Cargando…
Immunotherapy in Breast Cancer: the New Frontier
PURPOSE OF REVIEW: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. RECENT FINDINGS: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are on...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970253/ https://www.ncbi.nlm.nih.gov/pubmed/29881518 http://dx.doi.org/10.1007/s12609-018-0274-y |
_version_ | 1783326087313358848 |
---|---|
author | Hu, Zishuo I. McArthur, Heather L. |
author_facet | Hu, Zishuo I. McArthur, Heather L. |
author_sort | Hu, Zishuo I. |
collection | PubMed |
description | PURPOSE OF REVIEW: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. RECENT FINDINGS: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. SUMMARY: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes. |
format | Online Article Text |
id | pubmed-5970253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-59702532018-06-05 Immunotherapy in Breast Cancer: the New Frontier Hu, Zishuo I. McArthur, Heather L. Curr Breast Cancer Rep Translational Research (RL Aft, Section Editor) PURPOSE OF REVIEW: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. RECENT FINDINGS: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. SUMMARY: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes. Springer US 2018-04-16 2018 /pmc/articles/PMC5970253/ /pubmed/29881518 http://dx.doi.org/10.1007/s12609-018-0274-y Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Translational Research (RL Aft, Section Editor) Hu, Zishuo I. McArthur, Heather L. Immunotherapy in Breast Cancer: the New Frontier |
title | Immunotherapy in Breast Cancer: the New Frontier |
title_full | Immunotherapy in Breast Cancer: the New Frontier |
title_fullStr | Immunotherapy in Breast Cancer: the New Frontier |
title_full_unstemmed | Immunotherapy in Breast Cancer: the New Frontier |
title_short | Immunotherapy in Breast Cancer: the New Frontier |
title_sort | immunotherapy in breast cancer: the new frontier |
topic | Translational Research (RL Aft, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970253/ https://www.ncbi.nlm.nih.gov/pubmed/29881518 http://dx.doi.org/10.1007/s12609-018-0274-y |
work_keys_str_mv | AT huzishuoi immunotherapyinbreastcancerthenewfrontier AT mcarthurheatherl immunotherapyinbreastcancerthenewfrontier |